Statements (116)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquired_by |
gptkb:Abb_Vie
by Abb Vie |
| gptkbp:acquisition |
acquired by Lundbeck
|
| gptkbp:acquisition_year |
gptkb:2019
|
| gptkbp:business_model |
biopharmaceutical development
|
| gptkbp:can_lead_to |
gptkb:Eptinezumab
|
| gptkbp:ceo |
gptkb:Mark_J._Rothera
gptkb:Dr._Randall_C._Schatzman |
| gptkbp:class |
CGRP inhibitors
|
| gptkbp:clinical_study_results |
published in journals
|
| gptkbp:clinical_trial |
gptkb:Eptinezumab
Phase 2 Phase 3 trials randomized controlled trials innovative therapies multiple sites across the US positive results conducts clinical trials Phase 2 trials thousands of patients chronic migraine Phase 3 trials for Eptinezumab positive results in trials commercial stage multiple sites in the US Phase 1, 2, 3 |
| gptkbp:collaboration |
partnership with pharmaceutical companies
|
| gptkbp:collaborations |
academic institutions
with universities |
| gptkbp:commercialization_strategy |
direct sales and partnerships
|
| gptkbp:community_engagement |
patient advocacy groups
involved in patient advocacy |
| gptkbp:competitors |
other biopharmaceutical companies
|
| gptkbp:efficacy_data |
demonstrated in trials
|
| gptkbp:employees |
approximately 100
|
| gptkbp:financial_performance |
reported revenue growth
|
| gptkbp:financial_reports |
quarterly earnings
|
| gptkbp:financial_support |
resources for patients
|
| gptkbp:focus |
development of therapies for migraine
|
| gptkbp:focus_area |
monoclonal antibodies
|
| gptkbp:founded |
gptkb:2004
|
| gptkbp:founder |
gptkb:Dr._Randall_C._Schatzman
gptkb:Randall_C._Schatzman |
| gptkbp:funding |
gptkb:venture_capital
Series A, B, C received grants for research |
| gptkbp:grants |
government and private funding
|
| gptkbp:has_advisory_board |
comprised of industry experts
experts in neurology |
| gptkbp:head_of_state |
strategic partnerships
|
| gptkbp:headcount |
100-200
|
| gptkbp:headquarters |
gptkb:Bothell,_Washington
|
| gptkbp:healthcare |
gptkb:2020
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alder Bio Pharmaceuticals
|
| gptkbp:instruction_set |
multiple drug candidates
multiple candidates multiple therapeutic candidates |
| gptkbp:invention |
multiple patents for drug formulations
patents on monoclonal antibodies |
| gptkbp:investment |
institutional investors
Venture capital firms investor presentations secured funding from venture capital maintains communication with investors |
| gptkbp:investment_focus |
chronic migraine
migraine prevention market |
| gptkbp:investment_strategy |
traded on NASDAQ
|
| gptkbp:ipo |
gptkb:2017
|
| gptkbp:is_a_platform_for |
Ig G1 monoclonal antibodies
|
| gptkbp:leadership |
gptkb:CEO
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
on migraine treatments
|
| gptkbp:market_cap |
approximately $1 billion
|
| gptkbp:market_launch |
gptkb:2020
entered the migraine treatment market. launched Eptinezumab in 2020 |
| gptkbp:marketing_strategy |
focus on neurology
focus on migraine treatment |
| gptkbp:notable_products |
gptkb:Eptinezumab
|
| gptkbp:number_of_employees |
approximately 100
|
| gptkbp:partnership |
gptkb:collaboration
gptkb:Pfizer collaborated with Abb Vie |
| gptkbp:partnerships |
biopharmaceutical companies
with providers strategic alliances with other companies |
| gptkbp:patient_access_programs |
for Eptinezumab
|
| gptkbp:patient_population |
adults with migraines
|
| gptkbp:product |
gptkb:Eptinezumab
focus on innovative therapies |
| gptkbp:product_type |
gptkb:monoclonal_antibody
|
| gptkbp:publications |
peer-reviewed articles
publishes research findings |
| gptkbp:regulatory_compliance |
complies with FDA regulations
FDA approval for Eptinezumab FDA and EMA IND applications |
| gptkbp:research |
focused on migraine treatment
|
| gptkbp:research_areas |
neurology
neuroscience |
| gptkbp:research_focus |
gptkb:neurodegenerative_diseases
biologics preventive treatment for migraines |
| gptkbp:safety_features |
well-tolerated
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:stock_symbol |
ALDR
|
| gptkbp:subsidiary |
gptkb:Alder_Bio_Pharmaceuticals,_Inc.
|
| gptkbp:team |
experienced executives in biotech
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
www.alderbio.com
|
| gptkbp:bfsParent |
gptkb:GSK
gptkb:Regeneron gptkb:Takeda |
| gptkbp:bfsLayer |
4
|